International Clinical Trial: A Phase 1a/1b Dose-Escalation and Expansion Study of [¹77Lu]Lu-FAP-2286 Radioligand Therapy in Combination with Dual Immune Checkpoint Blockade (Nivolumab and Ipilimumab) in Patients with Unresectable or Advanced Malignant Pleural Mesothelioma (MPM)

Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ACTRN12626000505303) titled 'A Phase 1a/1b Dose-Escalation and Expansion Study of [¹77Lu]Lu-FAP-2286 Radioligand Therapy in Combination with Dual Immune Checkpoint Blockade (Nivolumab and Ipilimumab) in Patients with Unresectable or Advanced Malignant Pleural Mesothelioma (MPM)' on April 23.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Non-randomised trial Masking: Open (masking not used) Assignment: Single group Type of endpoint: Safety

Primary Sponsor: South Metropolitan Health Service

Condition: Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma Cancer - Lung - Mesothelioma

Intervention: ...